Access cutting-edge triple negative breast cancer treatment through this clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.
Access triple negative breast cancer specialists in Phoenix at no cost
This study follows strict safety protocols and ethical guidelines
All study-related triple negative breast cancer treatment provided free
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Sponsor: Gilead Sciences
Check if you qualify for this triple negative breast cancer clinical trial in Phoenix, AZ
If you're searching for triple negative breast cancer treatment options in Phoenix, AZ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Phoenix research site is actively enrolling participants for this clinical trial. You'll receive care from experienced triple negative breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.